Fig. 5.
The mechanism of in vitro anticancer effects of BCFe@SRF. The hepa 1–6 cells were treated with different formulations (Ce6 concentration: 1 μM) with or without laser irradiation (670 nm light, 50 mW·cm−2, 5 min) in normoxic or hypoxic condition. a The simplified mechanism of ferroptosis. b CCK-8 cell viability assay (*p < 0.05, **p < 0.01, ***p < 0.001, pairwise comparison; #p < 0.05, ##p < 0.01, ###p < 0.001, comparison between the same formulation in normoxic and hypoxic condition, n = 5). c Fluorescence microscopy images of hepa 1–6 cells treated with different formulations and ROS indicator DCFH-DA with or without laser irradiation in hypoxic condition. d CLSM images of hepa 1–6 cells treated with different formulations and LPO indicator BODIPY581/591-C11 in hypoxic condition. e The flow cytometry analysis of BODIPY581/591-C11 labeled hepa 1–6 cells treated with different formulations in hypoxic incubation. f The corresponding mean fluorescence intensity (MFI) of BODIPY581/591-C11 labeled hepa 1–6 cells analyzed by flow cytometry (*p < 0.05, **p < 0.01, ***p < 0.001, compared to the BCFe@SRF group, n = 3). g Intracellular GSH levels of the hepa 1–6 cells treated with different formulations (Ce6 concentration: 1 μM) in hypoxic condition. h Western blot analysis of intracellular GPX4 expression of hepa 1–6 cells treated with different formulations in hypoxic environment